The DOI matches its Crossref record; 117 of the 117 references it cites were found in a registry or an index.
Mendelian randomization: where are we now and where are we going?
Open accessAbstract
The methodology and application of Mendelian randomization to study causal mechanisms in health and disease has developed dramatically over the past decade. New methods, large-scale genome-wide analyses, molecular epigenetics and other new -omics technologies are all providing exceptional opportunities for the exploitation of Mendelian randomization approaches to understand causes of complex traits and disease outcomes. This research has the potential to identify new approaches for the prevention and treatment of common conditions. The origins of what is now termed ‘Mendelian randomization’ (Figure 1, see caption for assumptions) can be traced back over half a century,1 although the first extended presentation of the principles was in this journal just over a decade ago,2 Since then it has become a widely utilized methodology, with publications covering many branches of biomarker,3–12 behavioural13–16 and infectious disease17,18 epidemiology. Mendelian randomization studies with clear implications for pharmacotherapeutics are also becoming commonplace,19–21 and applications to social science and to economics (the field in which the statistical technique of instrumental variables analysis central to Mendelian randomization was initially conceived22) are being developed.23,24 Mendelian randomization: using genetic variants as instrumental variables to establish whether an exposure is causally related to a disease or trait. (A) The genotype acts as an instrumental variable if: (i) it is associated with the exposure; (ii) it is independent of measured or unmeasured confounders; and (iii) it can only influence that outcome via the causal effect of the exposure. (B) Under the instrumental variable assumptions, the lack of association between the C-reactive protein genotype and disease risk indicates that C-reactive protein is not a causal risk factor for ischaemic heart disease. An association between the genotype and disease outcome would indicate a causal relationship of the exposure on the outcome. Over the past few years, several methodological advances have been made. The basic assumption—that genetic variants which can proxy for a potentially modifiable exposure are essentially unrelated to confounding factors—has been demonstrated to have widespread plausibility.25 The connection between the standard Mendelian randomization experiment and the theory of instrumental variables has been elaborated upon.26,27 Extensions to use multiple genetic variants for increasing power and investigating the influence of pleiotropy have been theorized28 and implemented.29–32 Bidirectional Mendelian randomization for informing the direction of causal effects has been exemplified33,34 and extended to consider more complex networks.35 Methods for the estimation of non-linear causal effects have been proposed.36,37 Causal effects of related phenotypes with common genetic predictors in a multivariable analysis framework have been estimated.38,39 Factorial Mendelian randomization to predict the separate and combined effect of treatments using different genetic proxies has been undertaken.40 Sensitivity analyses for investigating the biasing effects of pleiotropy have been developed.41,42 Extensions to consider gene-by-environment interactions have been outlined and applied.43–45 The integration of epigenetic profiles as an intermediate phenotype has been proposed46,47 and implemented.48,49 The development of Mendelian randomization into the hypothesis-free resolution of causal directions in correlated networks has been outlined.50 In summary, methodological development has been undertaken in response to the challenges of new substantive applied questions and increasingly detailed genetic data. This development has enabled (and continues to enable) more sophisticated questions to be answered using the framework of Mendelian randomization. Initial applications of Mendelian randomization generally incorporated a single genetic variant, and assessed the causal relationship of the modifiable intermediate phenotype on the outcome in a single sample. The proliferation of genome-wide association study (GWAS) data, and in particular publicly available GWAS data51 (such as summary genetic associations with coronary artery disease in over 60 000 cases and 130 000 controls from the CARDIoGRAMplusC4D consortium52) provides opportunities to extend this via the use of the following. Increased sample sizes. Consortia with GWAS data on large sample sizes are available for many phenotypic traits and disease outcomes. This increases the power of Mendelian randomization investigations.53 Multiple genetic variants. For many intermediate phenotypes investigated in Mendelian randomization studies, GWAS investigations have been able to identify multiple genetic variants contributing to variation in the phenotype. Again, this increases the power of Mendelian randomization investigations.54 Two-sample Mendelian randomization. The ideal context for the pre
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bowden, J., Davey Smith, G., & Burgess, S. (2015) · International Journal of Epidemiology · doi:10.1093/ije/dyv080 · Cited by 9,816 · cited 2×
“ment of novel statistical tools for detecting and adjusting for pleiotropy from multiple genetic variants.(41)”
BackgroundMethodSelf-citationMendelian Randomization Analysis With Multiple Genetic Variants Using Summarized Data
Burgess, S., Butterworth, A., & Thompson, S. G. (2013) · Genetic Epidemiology · doi:10.1002/gepi.21758 · Cited by 6,050
Self-citationDavey Smith, G., & Ebrahim, S. (2003) · International Journal of Epidemiology · doi:10.1093/ije/dyg070 · Cited by 5,882
Self-citationGut flora metabolism of phosphatidylcholine promotes cardiovascular disease
Wang, Z., Klipfell, E., Bennett, B. J., Koeth, R., Levison, B. S., DuGar, B., Feldstein, A. E., Britt, E. B., Fu, X., Chung, Y.-M., et al. (2011) · Nature · doi:10.1038/nature09922 · Cited by 5,597
Mendelian randomization: genetic anchors for causal inference in epidemiological studies
Davey Smith, G., & Hemani, G. (2014) · Human Molecular Genetics · doi:10.1093/hmg/ddu328 · Cited by 4,677
Self-citationMendelian randomization: Using genes as instruments for making causal inferences in epidemiology
Lawlor, D. A., Harbord, R. M., Sterne, J. A. C., Timpson, N., & Davey Smith, G. (2008) · Statistics in Medicine · doi:10.1002/sim.3034 · Cited by 4,618
Self-citationAn atlas of genetic correlations across human diseases and traits
ReproGen Consortium, Bulik-Sullivan, B., Psychiatric Genomics Consortium, Genetic Consortium for Anorexia Nervosa of the Wellcome Trust Case Control Consortium 3, Finucane, H. K., Anttila, V., Gusev, A., Day, F. R., Loh, P.-R., Duncan, L., et al. (2015) · Nature Genetics · doi:10.1038/ng.3406 · Cited by 4,255
Metabolite profiles and the risk of developing diabetes
Wang, T. J., Larson, M. G., Vasan, R. S., Cheng, S., Rhee, E. P., McCabe, E., Lewis, G. D., Fox, C. S., Jacques, P. F., Fernandez, C., et al. (2011) · Nature Medicine · doi:10.1038/nm.2307 · Cited by 3,143
Metabolomics: the apogee of the omics trilogy
Patti, G. J., Yanes, O., & Siuzdak, G. (2012) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3314 · Cited by 2,571
Angrist, J. D., & Krueger, A. B. (2001) · Journal of Economic Perspectives · doi:10.1257/jep.15.4.69 · Cited by 2,355
Cited by
Murray, C. J. L., Aravkin, A. Y., Zheng, P., Abbafati, C., Abbas, K. M., Abbasi-Kangevari, M., Abd-Allah, F., Abdelalim, A., Abdollahi, M., Abdollahpour, I., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30752-2 · Cited by 9,854
Robust inference in summary data Mendelian randomization via the zero modal pleiotropy assumption
Hartwig, F. P., Davey Smith, G., & Bowden, J. (2017) · International Journal of Epidemiology · doi:10.1093/ije/dyx102 · Cited by 3,485
Mendelian Randomization as an Approach to Assess Causality Using Observational Data
Sekula, P., Del Greco M, F., Pattaro, C., & Köttgen, A. (2016) · Journal of the American Society of Nephrology · doi:10.1681/asn.2016010098 · Cited by 2,351
Yavorska, O. O., & Burgess, S. (2017) · International Journal of Epidemiology · doi:10.1093/ije/dyx034 · Cited by 2,052
Self-citationPsychiatric Genomics: An Update and an Agenda
Sullivan, P. F., Agrawal, A., Bulik, C. M., Andreassen, O. A., Børglum, A. D., Breen, G., Cichon, S., Edenberg, H. J., Faraone, S. V., Gelernter, J., et al. (2018) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2017.17030283 · Cited by 676
Metadata
- Authors
- Burgess, S., Timpson, N. J., Ebrahim, S., & Davey Smith, G.
- Venue
- International Journal of Epidemiology
- Publisher
- Oxford University Press (OUP)
- Published
- 2015-04-01
- Volume
- 44
- Issue
- 2
- Pages
- 379-388
- ISSN
- 0300-5771 (ISSN-L)
- 1464-3685
- OpenAlex
- W2143685991
- Cited by
- 304
- References
- 117
- FWCI
- 15.01
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Mendelian randomization: where are we now and where are we going? https://app.cochat.ai/papers/10.1093/ije/dyv108
- The paper
- Burgess, S., Timpson, N. J., Ebrahim, S., & Davey Smith, G. (2015). Mendelian randomization: where are we now and where are we going? International Journal of Epidemiology. https://doi.org/10.1093/ije/dyv108
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.